United States CRISPR Market Size, Share, Growth Analysis, and Forecast (2025-2033): Gene Editing Innovations Reshaping Therapeutics, Agriculture, and Biotechnology | Takara Bio Inc., QIAGEN, Eurofins Genomics.

CRISPR market reached US$ 3.93 billion in 2024 and is expected to reach US$ 15.92 billion by 2033, growing at a CAGR of 16.8% during the forecast period 2025-2033.

The global CRISPR market focuses on the development and commercialization of gene-editing technologies for therapeutics, agriculture, and research. CRISPR enables precise modification of genetic sequences for disease treatment and crop improvement. Growth is fueled by rising biotechnology investments and research applications. Ethical approvals and clinical trial progress guide adoption. Companies are expanding pipelines in oncology, rare diseases, and regenerative medicine. Innovations in delivery systems and off-target reduction enhance CRISPR applicability.

📌 Download Sample Report to Identify Emerging Deals & Opportunities in the Global CRISPR Market Landscape:- https://datamintelligence.com/download-sample/crispr-market?rk

☛ Global CRISPR Market Recent Developments 2025:

United States: Recent Industry Developments

✅ In August 2025, CRISPR Therapeutics reported promising mid-stage trial results for its ex vivo CRISPR-Cas9 therapy in treating sickle cell disease and beta-thalassemia, with durable clinical responses.

✅ In July 2025, Intellia Therapeutics expanded its pipeline with in vivo CRISPR therapies targeting hereditary angioedema and transthyretin amyloidosis, moving into Phase 2 studies.

✅ In June 2025, Editas Medicine announced FDA clearance to begin trials of a CRISPR-based gene-editing therapy for inherited retinal disorders, aiming to restore vision.

Europe: Recent Industry Developments

✅ In July 2025, Cellectis advanced development of its allogeneic CAR-T therapies using CRISPR technology, with trials across France and the UK for hematologic cancers.

✅ In June 2025, Evotec SE partnered with European research institutes to integrate CRISPR gene-editing platforms into drug discovery and target validation pipelines.

✅ In May 2025, Oxford University spin-outs accelerated CRISPR-based innovations in agriculture and biopharma, receiving new EU funding for precision editing technologies.

Japan: Recent Industry Developments

✅ In July 2025, Takeda Pharmaceutical launched a CRISPR-focused research program to develop gene-edited cell therapies for rare genetic disorders in Japan.

✅ In June 2025, Astellas Pharma collaborated with Japanese universities to pioneer CRISPR-Cas12 and base editing applications, focusing on in vivo delivery systems.

✅ In May 2025, Riken Institute advanced next-generation CRISPR tools for regenerative medicine, with applications in stem cell research and tissue engineering.

☛ FDA approvals process and pathways:

Preclinical testing - Laboratory and animal studies to evaluate safety and biological activity before human trials.

IND (Investigational New Drug) application - Required before starting clinical trials in humans; FDA reviews safety data, protocols, and manufacturing details.

Clinical trials

Phase I - Tests safety, dosage, and side effects in small groups.

Phase II - Evaluates efficacy and further safety in larger patient groups.

Phase III - Confirms effectiveness, monitors adverse reactions, and compares with standard treatments.

NDA/BLA submission - New Drug Application (for drugs) or Biologics License Application (for biologics) submitted with all trial data for FDA review.

Advisory committee review (if required) - Independent experts may evaluate evidence before approval.

FDA approval - Product can be marketed in the U.S. if proven safe and effective.

Medical devices - Reviewed under 510(k) clearance, De Novo pathway, or Premarket Approval (PMA) depending on risk classification (Class I, II, or III).

Expedited pathways - Programs like Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval speed access for serious or unmet medical needs.

Post-approval surveillance - Ongoing monitoring, adverse event reporting, labeling updates, and sometimes Phase IV studies to ensure long-term safety.

☛ Global CRISPR Market Competitve Landscape:

Thermo Fisher Scientific, Inc., Merck KGaA, Agilent Technologies, Inc., GenScript, Creative Biogene, Bio-Rad Laboratories, Inc., Takara Bio Inc., QIAGEN, Eurofins Genomics, and Synthego, among others.

Research Methodology

We follow a hybrid research approach, combining qualitative insights with rigorous quantitative analysis to deliver reliable and comprehensive market intelligence. Our process begins with extensive secondary research, drawing on trusted industry reports, proprietary databases, and credible market sources. This is then reinforced through targeted primary research, including structured surveys and in-depth interviews with industry leaders, subject matter experts, and key market participants.

📌 Request a Customized Market Report - Tailored insights to match your business goals: https://datamintelligence.com/customize/crispr-market

☛ Segment Covered in the Global CRISPR Market:

By Product Type: CRISPR kits & Consumables, CRISPR Libraries, Others.

By Application: Drug Discovery & Development, Agriculture, Others.

By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic & Research Institutes, Others.

☛ This Report Includes:

✔ Comprehensive go-to-market strategies with actionable insights.

✔ Unbiased evaluation of overall market performance.

✔ Deep-dive analysis into development trends, competitive landscape, supply-demand dynamics, YoY growth, benchmarking, vendor mapping, market access, and overall progress.

✔ Tailored regional and country-level reports with detailed localized analysis available on request.

✔ Identification of niche segments and high-growth regions presenting strong opportunities.

✔ Accurate regional forecasts using both top-down and bottom-up approaches.

📌 Get Corporate Access to Live Global CRISPR Industry Intelligence Database: https://www.datamintelligence.com/buy-now-page?report=crispr-market

☛ Regional Analysis for Global CRISPR Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

☛ Frequently asked questions:

➠ What is the global sales, production, consumption, import, and export value of the Global CRISPR Market?
➠ Who are the key global manufacturers, and what is their operational performance?
➠ What are the major opportunities and threats in the global Global CRISPR Market?
➠ Which product types or end-users show the most growth potential and market share?
➠ What challenges and constraints are impacting the Global CRISPR Market?
➠ What sales, marketing, and distribution channels are used globally?

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.